Finding patients who qualify for a clinical trial has always been one of the hardest parts of running one. In liver disease, particularly MASLD, it is especiall...
Continue reading
Liver disease remains one of the few major disease areas where outcomes have not improved in line with other fields such as cardiovascular disease and cancer. I...
Continue reading
Somerset, UK, 18th March 2026: Predictive Health Intelligence (PHI) and Sano Genetics today announced the completion of recruitment into the LiveWell study, wit...
Continue reading
Metabolic-associated steatotic hepatitis (MASH) is primarily managed through lifestyle modifications, such as adopting a restricted diet high in antiinflammator...
Continue reading
Recently on The Genetics Podcast, Patrick sat down with Dr. Erik Ingelsson, Chief Scientific Officer at Wave Life Sciences, to explore some of the most exciting...
Continue reading
Liver disease remains one of the leading causes of morbidity and mortality worldwide, presenting complex challenges in healthcare due to its multifaceted nature...
Continue reading
Last week, we attended the NASH-TAG conference in beautiful Park City, Utah. Against a winter wonderland backdrop, we dove deep into the latest research on meta...
Continue reading
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), is a complex liver disease characterized by fa...
Continue reading
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), is a progressive liver disease driven by fat a...
Continue reading
This webinar, hosted by Sano CEO Dr. Patrick Short and featuring Dr. Dimitar Tonev, an expert in liver disease and hepatology, sheds light on the latest develop...
Continue reading